Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Kenvue Inc.. A complete text table follows the diagram.
Tylenol, allergy, digestive and other self-care brands generate a disproportionate share of profit while skin, beauty and essential-health products broaden the growth portfolio.
Swipe to explore
The Sankey maps reported segment sales into reported segment-adjusted costs and operating income. The portfolio-funding framing compares segment contributions; it does not claim that cash is formally transferred from one segment to another.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Self Care | 1 | $1.7B | Pain, cough, allergy and digestive health |
| Skin Health and Beauty | 1 | $1.1B | Face, body, hair and sun care |
| Essential Health | 1 | $1.2B | Oral, baby, wound and women's health |
| Everyday health portfolio | 2 | $3.9B | Eight product categories across three segments |
| Product and segment costs | 3 | $2.8B | Adjusted cost of sales and other segment items |
| Adjusted segment operating income | 3 | $1.1B | 27.9% of segment sales |
| From | To | Value |
|---|---|---|
| Self Care | Everyday health portfolio | $1.7B |
| Skin Health and Beauty | Everyday health portfolio | $1.1B |
| Essential Health | Everyday health portfolio | $1.2B |
| Everyday health portfolio | Product and segment costs | $2.8B |
| Everyday health portfolio | Adjusted segment operating income | $1.1B |